



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY

Sublingual versus Vaginal Misoprostol for Medical Termination of Second Trimesteric Pregnancy

A Thesis

Submitted for partial fulfillment of Master degree
in Obstetrics and Gynecology

By

Dina Fawzi Mansour
M.B.B.Ch

Under Supervision of

Prof. Dr. Amr Hassan El-Shalakany

Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

Dr. Amr Helmy Yehia

Assistant Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2021**



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the **Most Beneficent** and **Merciful**, Who gave me the strength to accomplish this work,*

*My deepest gratitude to my supervisor, **Prof. Dr. Amr Hassan El-Shalakany**, Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.*

*I would like to express my great and deep appreciation and thanks to **Dr. Amr Helmy Yehia**, Assistant Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for his meticulous supervision, and his patience in reviewing and correcting this work,*

Special thanks to all staff members of Ain Shams University Maternity Hospital, who assisted me and provided all facilities to complete this work,

*Last but not least, I would like to thank my **Parents**, and all my **Family** members for their continuous encouragement, enduring me and standing by me.*

 *Dina Fawzi Mansour*

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	ii
List of Figures	iii
Introduction	1
Aim of the Work.....	3
Review of Literature	
Overview of Miscarriage	4
Misoprostol	14
Patients and Methods.....	30
Results.....	42
Discussion	61
Summary and Conclusion	72
References	75
Arabic Summary	—

List of Abbreviations

<i>Abbr.</i>	<i>Full-term</i>
CBC	: Complete blood count
HCT	: Hematocrit
Hb	: Hemoglobin
CS	: Cesarean Section
D&C	: Dilatation and curettage
DM	: Diabetes mellitus
FDA	: Food and Drug Administration
FHR	: Fetal heart rate
GTD	: Gestational trophoblastic disease
hCG	: Human chorionic gonadotropin
IUFD	: Intrauterine fetal death
MTP	: Medical Termination of Pregnancy
NAF	: National Abortion Federation
NSAIDs	: Non-steroidal anti inflammatory drugs
PG	: Prostaglandin
PID	: Pelvic inflammatory disease
PROM	: Premature rupture of membrane
Rh	: Rhesus
SD	: Standard deviation
SPSS	: Statistical package for social science
TB	: Tuberculosis

List of Tables

Table No.	Title	Page No.
Table (1):	Difference between Groups regarding Initial Characteristics	43
Table (2):	Difference between Groups regarding Indication of Abortion.....	44
Table (3):	Difference between Groups regarding Initial Vital Signs and Hb	47
Table (4):	Difference between Groups regarding Outcomes of Induction of Abortion.....	48
Table (5):	Difference between Groups regarding Rates of Complete Expulsion of the Fetus and Placenta Stratified by Gestational Age.....	52
Table (6):	Difference between Groups regarding Adverse Outcomes	53
Table (7):	Difference between Groups regarding Adverse Outcomes	55
Table (8):	Surgical intervention among the studied groups.....	60

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Prostaglandin and thromboxane biosynthesis	18
Figure (2):	Prostaglandin and thromboxane biosynthesis	19
Figure (3):	Dilatation of the cervix.....	25
Figure (4):	Introduction of the sharp curette	26
Figure (5):	Bar-Chart showing Difference between Groups regarding Indication of Abortion.....	45
Figure (6):	Bar-Chart showing Difference between Groups regarding Fetal Viability.....	45
Figure (7):	Bar-Chart showing Difference between Groups regarding Status of Fetal Membranes	46
Figure (8):	Box-and-Whisker Plot Chart showing Difference between Groups regarding Total Misoprostol Dose.....	49
Figure (9):	Box-and-Whisker Plot Chart showing Difference between Groups regarding Time-to-Complete Abortion.....	49
Figure (10):	Box-and-Whisker Plot Chart showing Difference between Groups regarding Time-to-Fetal Expulsion	50
Figure (11):	Box-and-Whisker Plot Chart showing Difference between Groups regarding Hospital Stay	50

Figure (12): Bar-Chart showing Difference between Groups regarding Need for Surgical Evacuation	51
Figure (13): Scale of satisfaction.....	55
Figure (14): Box-and-Whisker Plot-Chart showing Difference between Groups regarding Degrees of Satisfaction.....	56
Figure (15): Bar-Chart showing Difference between Groups regarding Rates of Unsatisfaction	56
Figure (16): Bar-Chart showing Difference between Groups regarding Need for Analgesia.....	57
Figure (17): Bar-Chart showing Difference between Groups regarding Rates of Vomiting	57
Figure (18): Bar-Chart showing Difference between Groups regarding Rates of Diarrhea	58
Figure (19): Bar-Chart showing Difference between Groups regarding Rates of Fever	58
Figure (20): Box-and-Whisker Plot-Chart showing Difference between Groups regarding Degrees of Satisfaction.....	59
Figure (21): Bar-Chart showing Difference between Groups regarding Rates of Unsatisfaction	59
Figure (22): Surgical intervention among the studied groups	60

Introduction

Miscarriage is defined as termination of pregnancy before the period of viability, which occurs at 20 weeks of gestation and the foetus weighing 500 g according to the definition of World Health Organization (WHO), but here in Egypt, age of fetal viability is 28 weeks; so, miscarriage is considered before this gestational age. About 40-60 million abortions occur per year globally. Medical abortion is a safe alternative to surgical methods (*Stabile et al., 2000*).

Abortion is done according to the laws of any country. Legally, therapeutic abortion means ending a pregnancy by a physician due to illness of the mother or the fetus (*Hasanzadeh et al., 2009*).

Mid-trimester abortion constitutes 10–15 % of all induced abortions but is responsible for two-thirds of all major complications. There is a gradual increase in second trimester abortions because of the wide-scale introduction of prenatal screening programs detecting women whose pregnancies are complicated by serious fetal abnormalities. During the last decade, medical methods for mid-trimester induced abortions have shown a considerable development and have become safe and more accessible (*Borgatta et al., 2011*).

Cervical priming prior to surgical termination of pregnancy reduces the risks of cervical injury, uterine perforation,

haemorrhage and incomplete uterine evacuation. Risk factors for cervical damage include patient age (more common in younger patients) and increasing gestation (especially among multigravida women), which is associated with an increased risk of uterine perforation (*Aronsson et al., 2004*).

The Royal College of Obstetricians and Gynaecologists recommends that cervical preparation is beneficial prior to suction termination and should be routine when the woman is under 18 or at gestation of >10 weeks (*O'Shea et al., 2020*).

The commonly used methods for cervical priming include laminaria tent in the United States and the prostaglandin analogues in the United Kingdom. In the United Kingdom, the prostaglandin E1 analogue gemeprost is most commonly used although studies have shown that misoprostol is an effective alternative (*Ashok et al., 2000*).

Various management protocols have been used for second trimester pregnancy termination. These includes surgical techniques (D&E) and medical approaches such as intra-amniotic prostaglandin (PG) F2 α instillation, PGE2 vaginal suppositories, PGE2 and high-dose oxytocin (*Tang et al., 2005*).

All these methods require hospitalization and have disadvantage of surgical trauma and anaesthetic complication. PGE1 analogue, misoprostol, originally used for the treatment of peptic ulcer, has been found to have uterotonic effect as well and is used for termination of pregnancy for great success (*Guix et al., 2005*).

Aim of the Work

The aim of this study is to compare the effectiveness, and safety of sublingual versus vaginal routes of administration of misoprostol in the medical treatment for termination of the second trimesteric abortions.

Overview of Miscarriage

The incidence of clinically obvious miscarriage is considered to be between 10% and 15% of all pregnancies, although the real incidence may be considerably higher (*Grudzinskas 1995; Howie 1995; Simpson, 1991*).

The wide spread use of ultrasound in early pregnancy for either specific reasons (for example, vaginal bleeding) or as a routine examination (*Neilson, 1998*) reveals 'non-viable pregnancies' destined inevitably to miscarry in due course. These are termed 'anembryonic pregnancies' (formerly called 'blighted ova') if no embryo has developed within the gestation sac, or 'missed abortions' if an embryo or fetus is present, but is dead.

Misoprostol has been shown to be an effective myometrial stimulant of the pregnant uterus, selectively binding to EP-2/EP-3 prostanoid receptors (*Senior, 1993*). It is rapidly absorbed orally and vaginally. Vaginally absorbed serum levels are more prolonged and vaginal misoprostol may have locally mediated effects (*Zieman, 1997*).

Although clotting problems occasionally occur in women with prolonged retention of a dead fetus, this is rare and does not usually happen within the first month after fetal death. There are, therefore, not pressing medical reasons to

terminate non-viable pregnancies. Although, anecdotally, many women favour early termination, so-called 'expectant management' (that is, awaiting spontaneous miscarriage) is a legitimate alternative and this policy should be considered in clinical care and in planning trials.

Misoprostol has emerged as a critical component of these regimens both as a stand-alone method and in combination with other medications like mifepristone. The combination of mifepristone and misoprostol is the most effective and fastest regimen (*Borgatta et al., 2011*).

However, mifepristone is not widely available and is expensive. Misoprostol is being more widely used because it is inexpensive and stable at room temperature. It can be absorbed via oral, vaginal, sublingual, buccal, and rectal routes. Initially, misoprostol was used orally for medical abortion. Many clinical trials have found vaginal administration to be more effective than oral administration (*Ashok et al., 1998*).

There has been suggestive evidence showing that absorption through vaginal route is inconsistent (*Singh et al., 1999*).

Recently, the use of sublingual misoprostol has been explored for medical abortion. A pharmacokinetic study has demonstrated that sublingual administration could achieve